|Photo by: Was a bee via Investiture Achievement|
Worldwide leaders gathered in London to examine the role of Artificial Intelligence in healthcare.
The Bioscience symposium highlighted neuroscience, most particularly the study of Alzheimer’s. It was discussed in the event that the field of bioscience continues to grow over the last few years including that in epigenomics, metagenomics, genomics, and metabolomics.
University of Sheffield’s Professor Winston Hide said: “We’ve learned that you cannot make a definite statement about a particular gene.” He also talked about Verubecestat, an experimental drug for the treatment of Alzheimer’s disease. “An important example is the recent failure of a BACE1 inhibitor for the treatment of Alzheimer’s disease,” the computational biology professor continues.
Hide believes that data reproducibility is one of the big issues where AI can be of use. This is because AI has the capacity to combine whole-genome data to determine the necessary pathways that could potentially be used as a target to develop a therapy.
According to Caswell Barry who works as a Principal Research Associate at UCL Cell & Development Biology,” We have about 18 billion neurons in the cerebral cortex, but there is not enough computational power to visualize it yet.”
Barry said that “deep learning” might be the solution so it can imitate brain’s ability to process information.
University of Sussex’s Professor Margaret Boden also says, “It is absolutely obvious that the potential of AI is huge, massive.” Being a professor who teaches cognitive sciences, Boden looks forward to AI’s potential in the future although she is concerned with its technical limitations as of the moment. “ It’s contribution is still small due to technical limitations.”
While data quality and accessibility remain their concern, BenevolentBio CEO Jackie Hunter is positive that significant advances will continue. “There will always be dinosaurs somewhere, but they will go extinct someday,” Hunter emphasized.